An Open-Label Randomized 2-Period 2-Sequence Crossover Study Comparing Pharmacokinetics Of ABT-494 From The Immediate-Release And Extended-Release Formulations Following Multiple-Dose Administration In Healthy Subjects.

Trial Profile

An Open-Label Randomized 2-Period 2-Sequence Crossover Study Comparing Pharmacokinetics Of ABT-494 From The Immediate-Release And Extended-Release Formulations Following Multiple-Dose Administration In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Upadacitinib (Primary) ; Upadacitinib
  • Indications Atopic dermatitis; Crohn's disease; Rheumatoid arthritis; Ulcerative colitis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 26 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top